Daily Cannabis News Brief for 8/25/2026
- The Empire State Green Standard Alliance will operate the first-ever cannabis consumer advocacy booth at the Great New York State Fair, offering information on responsible use, home cultivation, product labeling, and New York’s legal marijuana market during the 13-day event.
- The Connecticut Supreme Court ruled that differences between hemp and marijuana licensing do not justify blocking changes in land use, allowing Lasa Extract LLC’s marijuana cultivation and processing operation after overturning a town’s denial.
- The DEA is reviewing applications from three companies requesting permission to import THC and manufacture marijuana products, including synthetic THC, for research, clinical trials, and laboratory standards.
- The DEA released transcripts from its marijuana rescheduling hearing, noting federal recognition of marijuana’s accepted medical uses while acknowledging concerns about health risks, impaired driving, and illicit markets, and highlighted that over six million patients are now treated with medical marijuana across 43 U.S. jurisdictions.
The Empire State Green Standard Alliance will operate the first booth dedicated to a cannabis consumer advocacy organization in the history of the Great New York State Fair. The booth will provide information about responsible consumption, home cultivation, product labeling and New York’s legal marijuana market throughout the 13-day event, with each day recognizing a policymaker, industry group or other contributor.
The Connecticut Supreme Court unanimously ruled that differences between hemp and marijuana licensing cannot alone justify blocking a proposed change in land use. The justices found that Lasa Extract LLC’s proposed marijuana cultivation and processing operation was not materially different from the hemp operation already conducted at the Suffield property, leaving in place a lower court ruling overturning the town’s denial.
The Drug Enforcement Administration (DEA) is considering three company applications involving the importation of tetrahydrocannabinols and the manufacture of marijuana, marijuana extracts and synthetic THC. Experic LLC is seeking to import THC for research and clinical trials, Chemtos LLC wants to manufacture marijuana and marijuana extracts as laboratory reference standards, and Cambrex Charles City is seeking to manufacture synthetic THC in bulk.
The Drug Enforcement Administration (DEA) released roughly 2,500 pages of transcripts from its 11-day marijuana rescheduling hearing, documenting the government’s case for Schedule III and testimony from opponents. The record shows federal officials concluding that marijuana has accepted medical uses for pain, chemotherapy-related nausea and vomiting, and anorexia associated with a medical condition, while opponents focused on health risks, product inconsistency, impaired driving, workplace testing and illicit markets.
More than 30,000 health care practitioners are treating over six million medical marijuana patients across 43 U.S. jurisdictions, figures the Drug Enforcement Administration (DEA) says show “there is no longer a lack of accepted safety for use of marijuana under medical supervision.” The agency argues that the widespread medical use demonstrates that marijuana no longer meets the requirements for Schedule I.
Florida medical marijuana dispensaries sold more than 14.2 billion milligrams of THC and nearly 4.87 million ounces of smokable marijuana during the first eight months of 2026, according to data through August 21. The state reported 939,639 qualified patients with active identification cards and 776 dispensing locations, with Trulieve remaining the largest operator.
Illinois residents with sickle cell disease or polyendocrine metabolic ovarian syndrome accompanied by chronic pain can now qualify for the state’s medical marijuana program. The additions took effect immediately and increased the number of qualifying conditions recognized under the Medical Cannabis Patient Program to 58.
Law enforcement agencies reported 218,152 marijuana-related arrests in 2025, an increase of nearly 7% from the previous year, according to newly updated Federal Bureau of Investigation data. The total included 200,960 possession arrests and 17,192 arrests for sales or manufacturing, with possession accounting for approximately 92% of all reported marijuana arrests.